Commentary on "Seasonal Variation of Drug Prescription Rate for Overactive Bladder in Men Based on National Health Insurance Claims Data, 2012-2016".
作者信息
Tae Bum Sik, Bae Jae Hyun, Choi Hoon
机构信息
Department of Urology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
出版信息
Int Neurourol J. 2021 Mar;25(1):93-94. doi: 10.5213/inj.2142014.007. Epub 2021 Mar 31.
Abstract
摘要
相似文献
1
Commentary on "Seasonal Variation of Drug Prescription Rate for Overactive Bladder in Men Based on National Health Insurance Claims Data, 2012-2016".基于2012 - 2016年国家健康保险理赔数据对“男性膀胱过度活动症药物处方率的季节性变化”的评论
Int Neurourol J. 2021 Mar;25(1):93-94. doi: 10.5213/inj.2142014.007. Epub 2021 Mar 31.
2
Reply to the Commentary on "Seasonal Variation of Drug Prescription Rate for Overactive Bladder in Men Based on National Health Insurance Claims Data, 2012-2016".对《基于2012 - 2016年国民健康保险理赔数据的男性膀胱过度活动症药物处方率的季节性变化》评论的回复
Int Neurourol J. 2021 Mar;25(1):95-96. doi: 10.5213/inj.2142020.010. Epub 2021 Mar 31.
3
Seasonal Variation of Drug Prescription Rate for Overactive Bladder in Men Based on National Health Insurance Claims Data, 2012-2016.基于2012 - 2016年国家医疗保险理赔数据的男性膀胱过度活动症药物处方率的季节性变化
Int Neurourol J. 2020 Sep;24(3):278-285. doi: 10.5213/inj.2040030.015. Epub 2020 Sep 30.
4
Impact of a direct-to-consumer information campaign on prescription patterns for overactive bladder.一项面向消费者的宣传活动对膀胱过度活动症处方模式的影响。
BMC Health Serv Res. 2018 May 3;18(1):325. doi: 10.1186/s12913-018-3147-1.
5
The relative importance of health related quality of life and prescription insurance coverage in the decision to pharmacologically manage symptoms of overactive bladder.在决定对膀胱过度活动症症状进行药物治疗时，健康相关生活质量和处方药保险覆盖范围的相对重要性。
J Urol. 2007 Dec;178(6):2532-6; discussion 2536. doi: 10.1016/j.juro.2007.08.006. Epub 2007 Oct 15.
6
Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.美国过度膀胱活动症（OAB）和良性前列腺增生（BPH）的医疗管理模式。
Neurourol Urodyn. 2018 Jan;37(1):213-222. doi: 10.1002/nau.23276. Epub 2017 Apr 28.
7
Overactive bladder medication adherence when medication is free to patients.患者免费获得药物时，过度膀胱药物的用药依从性。
J Urol. 2010 Mar;183(3):1077-81. doi: 10.1016/j.juro.2009.11.026. Epub 2010 Jan 21.
8
Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis.日本膀胱过度活动症药物的持续性和依从性：一项大规模全国性真实世界分析。
Int J Urol. 2017 Oct;24(10):757-764. doi: 10.1111/iju.13422. Epub 2017 Aug 22.
9
The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.米拉贝隆用药持续与转换为注射用A型肉毒毒素对美国膀胱过度活动症患者的医疗成本和资源利用的影响。
J Med Econ. 2017 Dec;20(12):1272-1280. doi: 10.1080/13696998.2017.1367300. Epub 2017 Sep 4.
10
Bother related to bladder control and health care seeking behavior in adults in the United States.美国成年人中与膀胱控制及寻求医疗行为相关的困扰
J Urol. 2009 Jun;181(6):2591-8. doi: 10.1016/j.juro.2009.02.018. Epub 2009 Apr 16.
本文引用的文献
1
Seasonal Variation of Drug Prescription Rate for Overactive Bladder in Men Based on National Health Insurance Claims Data, 2012-2016.基于2012 - 2016年国家医疗保险理赔数据的男性膀胱过度活动症药物处方率的季节性变化
Int Neurourol J. 2020 Sep;24(3):278-285. doi: 10.5213/inj.2040030.015. Epub 2020 Sep 30.
2
Seasonal Variation of Overactive Bladder Symptoms in Female Patients.女性患者膀胱过度活动症症状的季节性变化
Int Neurourol J. 2019 Dec;23(4):334-340. doi: 10.5213/inj.1938078.039. Epub 2019 Nov 7.
3
α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database.α 受体阻滞剂与良性前列腺增生患者痴呆风险的关系：基于全国健康保险服务数据库的全国人群研究。
J Urol. 2019 Aug;202(2):362-368. doi: 10.1097/JU.0000000000000209. Epub 2019 Jul 8.
Zotero 插件